Latest news with #Doximity
Yahoo
2 days ago
- Business
- Yahoo
The Strong Earnings Posted By Doximity (NYSE:DOCS) Are A Good Indication Of The Strength Of The Business
Doximity, Inc.'s (NYSE:DOCS) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We did some digging and actually think they are being unnecessarily pessimistic. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking. Doximity has an accrual ratio of -0.29 for the year to March 2025. Therefore, its statutory earnings were very significantly less than its free cashflow. In fact, it had free cash flow of US$267m in the last year, which was a lot more than its statutory profit of US$223.2m. Doximity shareholders are no doubt pleased that free cash flow improved over the last twelve months. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Happily for shareholders, Doximity produced plenty of free cash flow to back up its statutory profit numbers. Based on this observation, we consider it possible that Doximity's statutory profit actually understates its earnings potential! And the EPS is up 47% annually, over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. At Simply Wall St, we have analyst estimates which you can view by clicking here. This note has only looked at a single factor that sheds light on the nature of Doximity's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 days ago
- Business
- Yahoo
Veeva Systems (VEEV) Reports Earnings Tomorrow: What To Expect
Healthcare software provider Veeva Systems (NASDAQ:VEEV) will be reporting earnings tomorrow after market hours. Here's what to look for. Veeva Systems beat analysts' revenue expectations by 3.1% last quarter, reporting revenues of $720.9 million, up 14.3% year on year. It was a strong quarter for the company, with an impressive beat of analysts' billings estimates and a solid beat of analysts' EBITDA estimates. Is Veeva Systems a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Veeva Systems's revenue to grow 12% year on year to $728.2 million, slowing from the 23.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.74 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Veeva Systems has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 1.6% on average. Looking at Veeva Systems's peers in the vertical software segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Doximity delivered year-on-year revenue growth of 17.1%, beating analysts' expectations by 3.5%, and Upstart reported revenues up 67%, topping estimates by 5.2%. Doximity traded down 10.1% following the results while Upstart was also down 9.7%. Read our full analysis of Doximity's results here and Upstart's results here. There has been positive sentiment among investors in the vertical software segment, with share prices up 7.3% on average over the last month. Veeva Systems is up 3% during the same time and is heading into earnings with an average analyst price target of $262.68 (compared to the current share price of $232.50). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
2 days ago
- Business
- Yahoo
3 High-Flying Stocks to Research Further
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly. Determining whether a company's quality justifies its price causes headaches for nearly all investors, which is why we started StockStory - to help you separate the real opportunities from the speculative ones. That said, here are three high-flying stocks expanding their competitive advantages. Forward P/S Ratio: 16.6x Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Do We Like DOCS? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time User-friendly software enables clients to ramp up spending quickly, leading to the speedy recovery of customer acquisition costs Strong free cash flow margin of 46.8% enables it to reinvest or return capital consistently At $51.80 per share, Doximity trades at 16.6x forward price-to-sales. Is now the time to initiate a position? Find out in our full research report, it's free. Forward P/E Ratio: 34.1x Formed from a merger of 12 companies, Curtiss-Wright (NYSE:CW) provides a range of products and services to the aerospace, industrial, electronic, and maritime industries. Why Is CW on Our Radar? Impressive 10.6% annual revenue growth over the last two years indicates it's winning market share this cycle Operating margin improvement of 4.7 percentage points over the last five years demonstrates its ability to scale efficiently Share repurchases have amplified shareholder returns as its annual earnings per share growth of 18.2% exceeded its revenue gains over the last two years Curtiss-Wright's stock price of $428.45 implies a valuation ratio of 34.1x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Forward P/E Ratio: 32.4x With low-pressure heating systems as the first product, Trane (NYSE:TT) designs, manufactures, and sells HVAC and refrigeration systems, the former to commercial and residential building customers and the latter to commercial truck manufacturers. Why Are We Bullish on TT? Annual revenue growth of 11.6% over the last two years was superb and indicates its market share increased during this cycle Share buybacks catapulted its annual earnings per share growth to 23.7%, which outperformed its revenue gains over the last two years Stellar returns on capital showcase management's ability to surface highly profitable business ventures, and its returns are climbing as it finds even more attractive growth opportunities Trane Technologies is trading at $424.60 per share, or 32.4x forward P/E. Is now a good time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Jim Cramer on Doximity (DOCS): 'I Cannot Get Behind That'
We recently published a list of . In this article, we are going to take a look at where Doximity, Inc. (NYSE:DOCS) stands against other stocks that Jim Cramer discussed recently. Noting that the stock tanked after earnings on weak guidance, a caller asked for Cramer's opinion of Doximity, Inc. (NYSE:DOCS), and he replied: 'That was a bad miss. That was a bad miss, and that's a high-growth company that had just been building up ahead of steam, and I cannot recommend that company because that was an unfathomable miss, frankly. And I feel very badly about saying that, but I was quite surprised. I cannot get behind that.' A pathologist and a laboratory assistant in a laboratory researching medical news and data. Doximity, Inc. (NYSE:DOCS) runs a digital platform designed for medical professionals and offers tools that support virtual care, career management, medical collaboration, and access to current research and news. The company also helps simplify administrative tasks and communication within the healthcare field. ClearBridge Investments stated the following regarding Doximity, Inc. (NYSE:DOCS) in its Q4 2024 investor letter: 'Doximity, Inc. (NYSE:DOCS), which offers a cloud-based collaboration platform for medical professionals that supports patient care and telehealth, was our top-performing holding in the sector. Shares rallied on a beat and raise quarter, with the company citing strong advertising revenue growth with impressive EBITDA flow through. Doximity has a history of consistent execution and, while it stumbled last year in effectively communicating realistic guidance and outlooks, it appears that management has regained investors' trust through several quarters of solid execution.' Overall, DOCS ranks 6th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of DOCS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DOCS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Jim Cramer on Doximity (DOCS): 'I Cannot Get Behind That'
We recently published a list of . In this article, we are going to take a look at where Doximity, Inc. (NYSE:DOCS) stands against other stocks that Jim Cramer discussed recently. Noting that the stock tanked after earnings on weak guidance, a caller asked for Cramer's opinion of Doximity, Inc. (NYSE:DOCS), and he replied: 'That was a bad miss. That was a bad miss, and that's a high-growth company that had just been building up ahead of steam, and I cannot recommend that company because that was an unfathomable miss, frankly. And I feel very badly about saying that, but I was quite surprised. I cannot get behind that.' A pathologist and a laboratory assistant in a laboratory researching medical news and data. Doximity, Inc. (NYSE:DOCS) runs a digital platform designed for medical professionals and offers tools that support virtual care, career management, medical collaboration, and access to current research and news. The company also helps simplify administrative tasks and communication within the healthcare field. ClearBridge Investments stated the following regarding Doximity, Inc. (NYSE:DOCS) in its Q4 2024 investor letter: 'Doximity, Inc. (NYSE:DOCS), which offers a cloud-based collaboration platform for medical professionals that supports patient care and telehealth, was our top-performing holding in the sector. Shares rallied on a beat and raise quarter, with the company citing strong advertising revenue growth with impressive EBITDA flow through. Doximity has a history of consistent execution and, while it stumbled last year in effectively communicating realistic guidance and outlooks, it appears that management has regained investors' trust through several quarters of solid execution.' Overall, DOCS ranks 6th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of DOCS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DOCS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
